FGF7 and ovarian carcinoma: Based on knowledge of the FGF7/FGFR2-IIIb interaction, bemarituzumab, which specifically targets FGF7’s receptor FGFR2b, would be of particular interest and may serve as a promising agent for future use in ovarian cancer.